CSIMarket
 
Matinas Biopharma Holdings Inc   (MTNB)
Other Ticker:  
 
 
Price: $0.1698 $0.00 1.921%
Day's High: $0.17 Week Perf: 3.85 %
Day's Low: $ 0.17 30 Day Perf: 6.39 %
Volume (M): 593 52 Wk High: $ 0.89
Volume (M$): $ 101 52 Wk Avg: $0.21
Open: $0.17 52 Wk Low: $0.11



 Market Capitalization (Millions $) 35
 Shares Outstanding (Millions) 209
 Employees 230
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Matinas Biopharma Holdings Inc
Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative lipid-based pharmaceuticals. The company was founded in 2011 and is headquartered in Bedminster, New Jersey. Matinas Biopharma Holdings Inc. is committed to improving patients' lives by developing products that target unmet medical needs in infectious and inflammatory diseases.

Matinas Biopharma Holdings Inc. is focused on developing its proprietary lipid nanocrystal (LNC) delivery technology, which enables the enhanced absorption and targeted delivery of a wide range of therapeutic agents. The LNC technology is designed to improve the bioavailability of poorly soluble drugs, reduce toxicity, and enhance therapeutic efficacy. It has the potential to significantly impact the treatment of infectious and inflammatory diseases, including HIV/AIDS, hepatitis C, and cryptococcal meningitis.

Matinas Biopharma Holdings Inc. has a broad pipeline of products in development. The lead product candidate is MAT9001, an omega-3 fatty acid-based cardiovascular drug. MAT9001 is a prescription-only, omega-3 free fatty acid drug that is designed to treat patients with high triglycerides, a risk factor for cardiovascular disease. The company is also developing MAT2203, a LNC-formulated amphotericin B drug for the treatment of invasive fungal infections, including aspergillosis and candidiasis. The drug is currently in Phase 2 clinical trials.

The company has a team of experienced leaders and scientists, with expertise in drug development, pharmaceutical manufacturing, clinical research, and regulatory affairs. Matinas Biopharma Holdings Inc. has partnerships and collaborations with leading academic institutions, pharmaceutical companies, and government agencies to accelerate the development of innovative therapeutics.

In summary, Matinas Biopharma Holdings Inc. is a rapidly evolving biopharmaceutical company that is committed to improving the delivery of therapeutic agents for patients suffering from infectious and inflammatory diseases. With a pipeline of products in development and a team of experienced leaders and scientists, the company is well-positioned to create new and innovative treatments that will impact the lives of patients in need.


   Company Address: 1545 Route 206 South Bedminster 7921 NJ
   Company Phone Number: 484-8805   Stock Exchange / Ticker: NYSEAMER MTNB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

MAT2203 A Game-Changer in Tackling Drug-Resistant Fungal Infections

Published Mon, Jun 24 2024 12:30 PM UTC

Matinas BioPharma Holdings, Inc. has recently reported a remarkable success in treating a 22-year-old male patient with polymicrobial necrotizing fasciitis caused by the drug-resistant fungus, Mucorales. This breakthrough achievement has been made possible through the application of Matinas' lipid nanocrystal (LNC) platform delivery technology and the use of their oral formu...

Clinical Study

Oral MAT2203 Revolutionizing Antifungal Treatment A Fireside Chat with Dr. David S. Perlin

Published Thu, Jun 13 2024 11:00 AM UTC

In an exciting development, the renowned CSIMarket.com is proud to present an exclusive fireside chat hosted by A.G.P., featuring esteemed antifungal expert, Dr. David S. Perlin, and pharmaceutical company Matinas BioPharma. This unique discussion centers around their innovative oral MAT2203 drug and its potential impact on the antifungal treatment landscape. In this artic...

Clinical Study

Matinas BioPharma's LNC Platform Shows Promise in Delivering Small Oligonucleotides and Treating Serious Infections

Published Thu, May 16 2024 11:00 AM UTC

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has recently presented new in vitro data highlighting the potential of its lipid nanocrystal (LNC) platform technology for delivering small oligonucleotides. This breakthrough was shared at the TIDES USA 2024 conference, which showcased advancements in oligonucleotide and peptide therapeutics. Additionally, the company's...

Clinical Study

Revolutionary Oral Drug MAT2203 Shows Promise in Combating Pulmonary Mucormycosis, Prolonging Survival and Reducing Fungal Burden, Study Shows

Published Tue, Apr 30 2024 12:01 PM UTC

Combining Science and Innovation: Matinas BioPharma's MAT2203 Shows Promise in Fighting Pulmonary MucormycosisStudies conducted on a neutropenic mouse model have revealed groundbreaking results in the battle against pulmonary mucormycosis. Matinas BioPharma's revolutionary oral drug, MAT2203, has demonstrated remarkable efficacy in improving lung infection, reducing fungal b...

Shares

Matinas BioPharma Raises $10 Million to Address Compliance and Drive Innovation in Biopharmaceutical Sector

Published Wed, Apr 3 2024 12:30 PM UTC

Matinas BioPharma Raises $10 Million in Direct Offering to Address Continued Listing Deficiency
Matinas BioPharma Holdings, Inc. recently announced a successful $10 million registered direct offering, issuing 33,333,334 shares of common stock and warrants to institutional investors. The offering, priced at $0.30 per share, aims to bolster the company's financial position...






 
  Company Estimates
  Revenue Outlook
Matinas Biopharma Holdings Inc does not provide revenue guidance.

Earnings Outlook
Matinas Biopharma Holdings Inc does not provide earnings estimates.

Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com